{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:38:59Z","timestamp":1786444739066,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41433-026-04567-1","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:46:45Z","timestamp":1779486405000},"page":"1846-1851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two-year treatment outcomes in neovascular age-related macular degeneration with type 3 macular neovascularisation"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-8541","authenticated-orcid":false,"given":"Yosuke","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-9755","authenticated-orcid":false,"given":"Satomi","family":"Shiose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Notomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Yuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohta","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"4567_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","volume":"21","author":"LA Yannuzzi","year":"2001","unstructured":"Yannuzzi LA, Negr\u00e3o S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416\u201334.","journal-title":"Retina"},{"key":"4567_CR2","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805\u201316.","journal-title":"N Engl J Med"},{"key":"4567_CR3","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751\u201361.","journal-title":"Ophthalmology"},{"key":"4567_CR4","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00417-024-06582-y","volume":"262","author":"Y Fukuda","year":"2024","unstructured":"Fukuda Y, Notomi S, Shiose S, Maehara Y, Kiyohara K, Fujiwara K, et al. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population. Graefes Arch Clin Exp Ophthalmol. 2024;262:3971\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4567_CR5","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","volume":"29","author":"M Engelbert","year":"2009","unstructured":"Engelbert M, Zweifel SA, Freund KB. \u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina. 2009;29:1424\u201331.","journal-title":"Retina"},{"key":"4567_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03053-w","volume":"11","author":"W Yoon","year":"2021","unstructured":"Yoon W, Yoon J, Na SK, Lee J, Kim J, Kim JW, et al. Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization. Sci Rep. 2021;11:23643.","journal-title":"Sci Rep"},{"key":"4567_CR7","doi-asserted-by":"crossref","unstructured":"Maehara Y, Notomi S, Shiose S, Fukuda Y, Kiyohara K, Kano K, et al. Switching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration. Jpn J Ophthalmol. 2026;70:150\u2013156.","DOI":"10.1007\/s10384-025-01264-6"},{"key":"4567_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10384-025-01178-3","volume":"69","author":"Y Fukuda","year":"2025","unstructured":"Fukuda Y, Shiose S, Notomi S, Maehara Y, Mori K, Hashimoto S, et al. Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients. Jpn J Ophthalmol. 2025;69:371\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"4567_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/bjo.2009.167627","volume":"94","author":"TS Hemeida","year":"2010","unstructured":"Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA. Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol. 2010;94:701\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4567_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1755-3768.2010.01952.x","volume":"90","author":"CA Kramann","year":"2012","unstructured":"Kramann CA, Sch\u00f6pfer K, Lorenz K, Zwiener I, Stoffelns BM, Pfeiffer N. Intravitreal ranibizumab treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2012;90:487\u201391.","journal-title":"Acta Ophthalmol"},{"key":"4567_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/bjo.2007.115501","volume":"91","author":"SY Cohen","year":"2007","unstructured":"Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F, et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol. 2007;91:1173\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4567_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15\u201322.","journal-title":"Am J Ophthalmol"},{"key":"4567_CR13","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"4567_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150\u201361.","journal-title":"Ophthalmology"},{"key":"4567_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915\u201324.e912.","journal-title":"Am J Ophthalmol"},{"key":"4567_CR16","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/IAE.0000000000001104","volume":"36","author":"H Matsumoto","year":"2016","unstructured":"Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, et al. Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina. 2016;36:2282\u20139.","journal-title":"Retina"},{"key":"4567_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679\u201380.","journal-title":"Am J Ophthalmol"},{"key":"4567_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3928\/23258160-20150521-01","volume":"46","author":"KB Freund","year":"2015","unstructured":"Freund KB, Engelbert M, Fine HF. Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. Ophthalmic Surg Lasers Imaging Retina. 2015;46:508\u201312.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4567_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125:537\u201348.","journal-title":"Ophthalmology"},{"key":"4567_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25860-5","volume":"12","author":"JH Kim","year":"2022","unstructured":"Kim JH, Kim JW, Kim CG. Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. Sci Rep. 2022;12:22546.","journal-title":"Sci Rep"},{"key":"4567_CR21","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1167\/iovs.15-18837","volume":"57","author":"J Baek","year":"2016","unstructured":"Baek J, Lee JH, Kim JY, Kim NH, Lee WK. Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2016;57:1500\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4567_CR22","first-page":"2115","volume":"40","author":"I Kim","year":"1999","unstructured":"Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4567_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","volume":"33","author":"I Bhutto","year":"2012","unstructured":"Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex. Mol Aspects Med. 2012;33:295\u2013317.","journal-title":"Mol Aspects Med"},{"key":"4567_CR24","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s00417-025-06945-z","volume":"263","author":"Y Fukuda","year":"2025","unstructured":"Fukuda Y, Shiose S, Notomi S, Maehara Y, Mori K, Kano K, et al. Six-month outcomes of half-fluence photodynamic therapy combined with intravitreal Aflibercept injection for pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol. 2025;263:3121\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4567_CR25","doi-asserted-by":"publisher","unstructured":"Fukuda Y, Notomi S, Shiose S, Maehara Y, Yuge K, Kiyohara K, et al. Wide-field choroidal thickness changes after loading-phase anti-VEGF therapy in treatment-na\u00efve neovascular AMD. Graefes Arch Clin Exp Ophthalmol. 2026. https:\/\/doi.org\/10.1007\/s00417-026-07130-6.","DOI":"10.1007\/s00417-026-07130-6"},{"key":"4567_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000481262","volume":"59","author":"A Martins","year":"2018","unstructured":"Martins A, Farinha C, Raimundo M, Lopes M, Santos AR, Melo P, et al. Multimodal evaluation of the fellow eye of patients with retinal angiomatous proliferation. Ophthalmic Res. 2018;59:88\u201397.","journal-title":"Ophthalmic Res"},{"key":"4567_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","volume":"98","author":"S Julien","year":"2014","unstructured":"Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98:813\u201325.","journal-title":"Br J Ophthalmol"},{"key":"4567_CR28","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1364\/BOE.427819","volume":"12","author":"EM Moult","year":"2021","unstructured":"Moult EM, Shi Y, Zhang Q, Wang L, Mazumder R, Chen S, et al. Analysis of correlations between local geographic atrophy growth rates and local OCT angiography-measured choriocapillaris flow deficits. Biomed Opt Express. 2021;12:4573\u201395.","journal-title":"Biomed Opt Express"},{"key":"4567_CR29","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1097\/IAE.0000000000001457","volume":"37","author":"M Hata","year":"2017","unstructured":"Hata M, Yamashiro K, Oishi A, Ooto S, Tamura H, Miyata M, et al. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina. 2017;37:2069\u201377.","journal-title":"Retina"},{"key":"4567_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","volume":"159","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, et al. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol. 2015;159:285\u201392.e281.","journal-title":"Am J Ophthalmol"},{"key":"4567_CR31","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.oret.2024.11.011","volume":"9","author":"R Sacconi","year":"2025","unstructured":"Sacconi R, Forte P, Corradetti G, Costanzo E, Capuano V, Bousquet E, et al. Type 3 macular neovascularization in age-related macular degeneration: baseline predictors of 3-year macular atrophy development. Ophthalmol Retina. 2025;9:546\u201355.","journal-title":"Ophthalmol Retina"},{"key":"4567_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/IAE.0b013e3181fe54c7","volume":"31","author":"VA McBain","year":"2011","unstructured":"McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina. 2011;31:1043\u201352.","journal-title":"Retina"},{"key":"4567_CR33","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41433-023-02918-w","volume":"38","author":"AE Sepetis","year":"2024","unstructured":"Sepetis AE, Barbara R, Frisina R, Farag M, De Salvo G. Functional and structural characteristics in patients with type 3 macular neovascularisation treated with anti-VEGF. Three-year results in real world settings. Eye 2024;38:1438\u201343.","journal-title":"Eye"},{"key":"4567_CR34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000540194","volume":"67","author":"L Toto","year":"2024","unstructured":"Toto L, Viggiano P, Quarta A, Grassi M, De Nicola C, Aloia R, et al. Effect of Pro Re Nata regimen with anti-VEGF on type 3 macular neovascularization: long-term outcomes. Ophthalmic Res. 2024;67:282\u201391.","journal-title":"Ophthalmic Res"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04567-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04567-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04567-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:21:59Z","timestamp":1786443719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04567-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4567"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04567-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7961029\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved with a waiver of informed consent through the Institutional Review Board at Kyushu University, Fukuoka, Japan (REB #26-131), and adhered to the tenets of the Declaration of Helsinki. All data were anonymised prior to analysis.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}